Job title: Director, Pharmacokinetics
Dr. Rupert Davies currently serves as a Principal Scientist at Zymeworks, where he is responsible for the development of ADCs. Dr. Davies enabled the advancement of ZW25 and ZW49 into the clinic and now focuses on combining Zymeworks’ Azymetric™ and ZymeLink™ platforms to develop ADCs with expanded therapeutic windows. He has worked on five candidates being evaluated in clinical trials and two approved drugs. Prior to his current role, Dr. Davies worked in various roles at start-ups to large biotechs. He received his PhD in Bioengineering from the University of Utah and completed a post-doc at the University of Washington.